Hyperthermia European Adjuvant Trial (HEAT)
Prospective randomized phase III clinical trial
EudraCTNumber: 2008-004802-14
AIO Number: AIO-PAK-0111

Amendment 2

Resectable Pancreatic Cancer

Surgical Resection
R0/R1 (N+/-, M0)

↓

Staging

↓

Randomization
Start of study

Start: 4-8 weeks postop.

Arm G (n= 168):
gemcitabine 1000 mg/m²
days 1, 8 and 15

total number of courses: 6

Arm G + Cis + RHT (n= 168):
gemcitabine 1000 mg/m²
days 1 and 15

cisplatin 25mg/m² with regional hyperthermia
days 2, 3 and 16, 17

total number of courses: 6

Follow Up